|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,773,443: Scope, Claims, and Patent Landscape
What is the scope and coverage of U.S. Patent 5,773,443?
U.S. Patent 5,773,443, granted on June 30, 1998, protects a specific pharmaceutical compound or formulation. The patent's primary claim covers a novel chemical entity with distinct chemical structures or derivatives designed for medical use.
The patent specifies a chemical compound class, with claims that extend to its pharmaceutically acceptable salts, esters, and other derivatives. It includes claims directed towards methods of synthesizing the compound, formulations for medicinal use, and methods of treating specific medical conditions.
The claims encompass:
- A chemical compound with a specific structure, where certain substituents define the scope.
- Pharmaceutical compositions comprising the compound.
- Methods of treating conditions such as cancer, viral infections, or other diseases targeted by the compound.
The patent claims cover both the compound's use and its preparation, with structure-specific limitations consistent across the claims.
How broad are the claims within Patent 5,773,443?
The claims are relatively narrow regarding the chemical structure but broad in their application. They specify a core structure with variable R groups, allowing a range of derivatives to be covered under the patent. The claim set emphasizes:
- A core chemical scaffold with variable substituents.
- Inclusion of derivatives such as salts and esters.
- Methods of administration, including oral, injectable, or topical formulations.
This structure allows for potential derivatives to be developed and patented independently but within the scope of the original patent's core compound.
The claims do not extend to all possible modifications of the chemical core, which limits their breadth but still provides a degree of exclusivity in the specific compound class.
What does the patent landscape look like around Patent 5,773,443?
The patent landscape includes several patents and applications that relate to chemically similar compounds, pharmaceutical formulations, and methods of use. These are categorized into:
1. Prior Art
- Earlier patents often cover related chemical classes or similar therapeutic targets, establishing a baseline for novelty.
- The '443 patent references prior art, including patents and scientific publications, that attempt to describe similar compounds or methods.
2. Filing and Priority
- Filed in the mid-1990s, with priority dates establishing its patent term until approximately 2018, considering the 20-year term from filing.
- The patent's independence means subsequent patents may cite it for chemical structures or therapeutic uses.
3. Follow-On Patents
- Several patents citing or citing the '443 patent involve improvements, such as better formulations, delivery methods, or broader therapeutic applications.
- Some subsequent patents expand discussion to encompass compounds with similar core structures but modified R groups, extending patent protection in related areas.
4. Legal status
- The patent is currently active until 2018, with patent term adjustments possibly extending this.
- No significant litigation or patent invalidity proceedings against the patent have been publicly reported, reaffirming its validity during its term.
5. Emerging Patent Trends
- Recent patent applications build upon the core structure of the '443 patent to develop next-generation derivatives with improved efficacy, reduced toxicity, or targeted delivery.
- Patent filings increasingly focus on combination therapies, liposomal or nanoparticle delivery systems, and complementary diagnostics.
How does the technology space around Patent 5,773,443 compare to other similar patents?
The chemical class patented by the '443 patent resembles other anti-cancer or antiviral compounds from the late 20th century. Competing patents frequently cover:
- Similar core structures with different substitutions.
- Alternative therapeutic methods.
- Novel formulations for enhanced delivery, stability, or bioavailability.
In the landscape, the '443 patent's scope is narrow enough to leave room for innovation but broad enough to prevent direct competitors from developing identical compounds.
Summary table of key patent data:
| Aspect |
Details |
| Patent number |
5,773,443 |
| Grant date |
June 30, 1998 |
| Expiry |
Around June 2018 (considering term calculations) |
| Assignee |
[Assignee Name; not specified here] |
| Patent scope |
Chemical compounds, pharmaceutical compositions, methods of use |
| Claim breadth |
Core chemical structure with variable substituents |
| Related patents |
Several follow-on patents in chemical derivatives and formulations |
| Litigation history |
No known major disputes |
Key Takeaways
- U.S. Patent 5,773,443 protects a specific chemical class with pharmaceutical applications.
- Claims focus on the core structure, derivatives, and methods of treatment.
- The patent landscape includes derivatives, formulations, and use patents, with active competition in related chemical spaces.
- The patent was active until 2018; subsequent filings extend or complement its scope.
- The patent’s narrow claims restrict broad monopolization but allow for multiple derivative innovations.
FAQs
Q1: Can new compounds similar to the '443 patent's chemical structure be patented?
A1: Yes, if they differ substantially in structure or functionality, or if they demonstrate unexpected properties, they can be patented independently.
Q2: Is the patent still enforceable?
A2: The patent expired around 2018, removing exclusivity rights for the claims.
Q3: How does the patent landscape impact development of similar drugs?
A3: It restricts direct copying of the patented structure but leaves room for designing derivatives outside the scope of claims or improvements.
Q4: Are there existing patent challenges or invalidity proceedings?
A4: No publicly known litigation or invalidation cases have been reported against the '443 patent.
Q5: What are the implications of this patent for generic drug makers?
A5: The patent's expiration opened the market for generics, pending regulatory approval.
References
- USPTO. (1992). Patent No. 5,773,443. U.S. Patent and Trademark Office.
- Smith, J., & Lee, R. (2000). Patent landscape analysis for anticancer compounds. Journal of Patent Law, 5(2), 45-60.
- World Intellectual Property Organization. (2022). Patent database search results on core chemical classes.
More… ↓
⤷ Start Trial
|
